Cerebral Dopamine Neurotrophic Factor
Recombinant proteinexperimental
Clinical trial activity
2 trials · 3 clinical orgs · 0 marketing orgs
Phase 1
2
Phase 2
2
Phase 3
0
Phase 4
0
Earliest trial started Sep 26, 2017 (NCT03295786)
Timeline
2010s
- Jan 1, 2017
Earliest Phase 1 Sponsor(trial)
Indications
Mechanism of action
- Cerebral dopamine neurotrophic factorSupplementation
CDNF supplementation
Chemistry & pharmacology
- Multi-specific
- No
Oral
No
Parenteral
No
Topical
No
Sources
- NCATSBA99H4C2PR ↗
Clinical trials
| NCT ID | Phase | Start date | Sponsor(s) |
|---|---|---|---|
| NCT03775538 | Phase 1/Phase 2 (Phase 2) | Jul 5, 2018 | Herantis Pharma Plc., Karolinska Institute, Renishaw plc. |
| NCT03295786 | Phase 1/Phase 2 (Phase 2) | Sep 26, 2017 | Herantis Pharma Plc., Karolinska Institute, Renishaw plc. |
Showing 2 of 2 trials
Page 1 / 1
Organizations
Research & Development (3)
| Organization | Org type | Trials | As lead sponsor | Phases | Earliest year |
|---|---|---|---|---|---|
| Herantis Pharma Plc. | For profit | 2 | 2 | 1 | 2017 |
| Karolinska Institute | Academic/Hospital | 2 | 0 | 1 | 2017 |
| Renishaw plc. | For profit | 2 | 0 | 1 | 2017 |
3 organizations
Page 1 / 1